Panbela Therapeutics (PBLA) Stock Price, News & Analysis

Company Overview

Panbela Therapeutics, Inc. (NASDAQ: PBLA) is a clinical‐stage biotechnology company focused on developing first‐in‐class therapies that modulate polyamine metabolism to treat aggressive cancers. The company’s lead investigational compound, SBP-101, is a proprietary stabilized spermine analogue designed to induce tumor cell apoptosis by dysregulating polyamine levels. Panbela has centered its pipeline largely on SBP-101 in combination with standard‐of‐care regimens for high‐mortality indications such as metastatic pancreatic adenocarcinoma and high‐risk myelodysplastic syndromes (HR-MDS).

In its pancreatic cancer program, Panbela is evaluating SBP-101 alongside gemcitabine and nab-paclitaxel in a Phase 1b/2 study, with interim data having been presented at major oncology conferences. A separate Phase 1/2 study is assessing SBP-101 plus azacitidine in patients with HR-MDS. The company continues to explore additional solid‐tumor and hematologic indications where polyamine pathway disruption may offer therapeutic benefit.

Headquartered in Minneapolis, Minnesota, Panbela Therapeutics operates as a public company listed on the Nasdaq Global Market. The organization emerged from a series of technology transfers aimed at commercializing novel polyamine modulators. Panbela’s executive leadership is led by President and Chief Executive Officer Michael B. MacDougall, M.D., with Christine Cannella serving as Chief Financial Officer.

Panbela conducts its clinical trials primarily in the United States and is actively pursuing global regulatory strategies. The company collaborates with leading academic cancer centers to advance its development programs and prepare for potential regulatory filings in both North American and international markets.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.0001 to $0.0111
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 581 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/10/2023
• Today: 9/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:PBLA
• CIK: 1029125
• Web: www.panbela.com
• Phone: (952) 479-1196
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,850,000
• Free Float: 4,855,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 42.77